Equity and Access in the Psychedelic Therapy Debate

As psilocybin and other psychedelics move through clinical trials and regulatory pathways worldwide, the conversation is shifting from whether these substances work to who will get to use them. In South Africa, psilocybin remains a Schedule 7 substance under the Medicines Act, meaning it is strictly prohibited. However, looking at international developments—such as the rescheduling of psilocybin in Australia and ongoing research at institutions like Johns Hopkins University—a critical policy question is emerging. If psychedelic therapy becomes legally regulated, will it be accessible to the general public, or will it become a luxury available only to the wealthy? Ensuring equitable access is becoming one of the central debates in modern drug policy reform.

The promise of psychedelic therapy offers hope for conditions like treatment-resistant depression and post-traumatic stress disorder (PTSD). Yet, without deliberate policy frameworks, the medical integration of these substances risks replicating the inequalities already present in the global healthcare landscape. Addressing these concerns requires looking at the cost of clinical models, the lessons of previous drug reforms, and proposals for inclusive public health approaches.

The High Cost of the Clinical Model

The primary driver of cost in regulated psychedelic therapy is the treatment model itself. Unlike conventional psychiatric medications, where the cost is largely in the manufacturing of the pill, psychedelic therapy involves intensive human resources. Current clinical frameworks typically require multiple preparatory therapy sessions, a supervised dosing session that can last six to eight hours, and several follow-up integration sessions to help patients process the experience.

This resource-heavy model means that therapists must dedicate significant time to a single patient. If this framework is mandated by regulators—such as the South African Health Products Regulatory Authority (SAHPRA) or the US Food and Drug Administration (FDA)—the out-of-pocket costs per patient could be prohibitively high. Early estimates from emerging regulated markets suggest that a single course of treatment could cost thousands of dollars, placing it out of reach for most public health systems and average citizens, particularly in lower- and middle-income countries.

The Risk of a Psychedelic Divide

Mental health conditions do not discriminate by income, yet access to treatment often does. There is a growing concern among researchers and ethicists that a "psychedelic divide" could emerge. If regulated therapy is too expensive, it risks excluding the very populations that might benefit most, including marginalised communities with high rates of trauma and systemic stress. Historically, these same communities have borne the brunt of the War on Drugs; denying them access to the therapeutic benefits of substances like psilocybin would compound that historical injustice.

Furthermore, many advocates point out a deep ethical tension. Indigenous communities have used psilocybin-containing mushrooms in ceremonial contexts for centuries. If Western pharmaceutical companies patent synthetic derivatives or proprietary therapeutic methods, and subsequently price them out of reach of the public, it perpetuates a cycle of extraction and inequity. The benefits of the psychedelic renaissance risk being locked behind expensive paywalls, turning a potentially transformative public health tool into an exclusive wellness product.

Lessons from the Cannabis Precedent

South Africa’s experience with cannabis offers a cautionary tale for psychedelic reform. Despite the legalisation of cannabis cultivation for personal use by adults following a Constitutional Court judgment, the broader commercial regulatory framework has heavily favoured well-capitalised entities. This has made legally produced, commercial cannabis expensive, pushing poorer consumers toward the unregulated market. The delays in licensing and the high costs of compliance have effectively shut out small-scale growers and community enterprises.

If psilocybin follows a similar path—where regulations are designed solely for high-end clinics, pharmaceutical companies, and wealthy investors—it risks recreating the same two-tiered system. A legal market that only serves the wealthy leaves the rest of the population to navigate the risks of an unregulated market. This undermines the public health goals of regulation and ensures that the safest, highest-quality therapies remain a privilege rather than a right.

Policy Proposals for Inclusive Access

To prevent psychedelics from becoming an exclusive luxury, policy experts and advocates are exploring several models to promote equity. One approach is integrating psychedelic therapy into public health systems. In South Africa, this might eventually involve exploring coverage under the proposed National Health Insurance (NHI) scheme, provided the therapies are proven cost-effective compared to long-term psychiatric care. Other proposals include establishing sliding-scale community clinics, subsidising training for practitioners from diverse backgrounds, and prioritising non-profit models of delivery over pure commercialisation.

Some jurisdictions, such as Oregon in the United States, have experimented with regulated service centres outside the traditional medical system. Some policy analysts argue that separating the substance from expensive clinical overheads—while still maintaining safety and harm-reduction standards—could eventually lower costs. Ultimately, embedding equity provisions into the initial scheduling and regulatory frameworks, rather than treating them as an afterthought, will be crucial to ensuring that psychedelic reform benefits society as a whole.